All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type ECOG ⩾ 1 ECOG 0 ECOG 1 Gender, female Gender, male Hemoglobin concentration < 10g/dl hemoglobin concentration > 10g/dl metastasis (liver ) metastasis (lymph node ) metastasis (visceral) PD-L1 < 1% PD-L1 < 10% PD-L1 < 5% PD-L1 > 1% PD-L1 > 10% PD-L1 > 5% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC) PDL1 < 25% PDL1 >25% smoker (current or former) smoker (Current) smoker (Former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
urothelial cancer (UC) - bladder cancer (BC), anti-PD-(L)1 vs. non active control, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMvigor-010, 2021 0.85 [0.66; 1.09]
JAVELIN Bladder 100 (all population), 2020 0.69 [0.56; 0.86]
JAVELIN Bladder 100 (PDL1>25%), 2020 0.56 [0.40; 0.79]
0.70 [0.57 ; 0.87 ] IMvigor-010, 2021, JAVELIN Bladder 100 (all population), 2020, JAVELIN Bladder 100 (PDL1>25%), 2020 3 49% 1,867 moderate not evaluable deaths (OS) (extension)detailed results JAVELIN Bladder 100 (all population), 2020 0.76 [0.63; 0.92]
JAVELIN Bladder 100 (PDL1>25%), 2020 0.69 [0.52; 0.91]
0.74 [0.63 ; 0.86 ] JAVELIN Bladder 100 (all population), 2020, JAVELIN Bladder 100 (PDL1>25%), 2020 2 0% 1,058 moderate not evaluable PFS (extension)detailed results JAVELIN Bladder 100 (all population), 2020 0.54 [0.45; 0.64]
JAVELIN Bladder 100 (PDL1>25%), 2020 0.46 [0.36; 0.59]
0.51 [0.44 ; 0.59 ] JAVELIN Bladder 100 (all population), 2020, JAVELIN Bladder 100 (PDL1>25%), 2020 2 9% 1,058 moderate not evaluable progression or deaths (PFS)detailed results JAVELIN Bladder 100 (all population), 2020 0.62 [0.52; 0.74]
JAVELIN Bladder 100 (PDL1>25%), 2020 0.56 [0.43; 0.73]
0.60 [0.52 ; 0.70 ] JAVELIN Bladder 100 (all population), 2020, JAVELIN Bladder 100 (PDL1>25%), 2020 2 0% 1,058 moderate not evaluable RFS/DFSdetailed results CheckMate 274 (all population), 2017 0.72 [0.59; 0.88]
CheckMate 274 (PDL1>1%), 2017 0.55 [0.39; 0.78]
0.65 [0.51 ; 0.84 ] CheckMate 274 (all population), 2017, CheckMate 274 (PDL1>1%), 2017 2 40% 991 low not evaluable DCRdetailed results JAVELIN Bladder 100 (all population), 2020 1.85 [1.35; 2.54]
JAVELIN Bladder 100 (PDL1>25%), 2020 2.03 [1.31; 3.16]
1.91 [1.48 ; 2.47 ] JAVELIN Bladder 100 (all population), 2020, JAVELIN Bladder 100 (PDL1>25%), 2020 2 0% 1,058 moderate not evaluable DMFSdetailed results CheckMate 274 (all population), 2017 0.75 [0.59; 0.95]
CheckMate 274 (PDL1>1%), 2017 0.61 [0.42; 0.89]
0.71 [0.58 ; 0.86 ] CheckMate 274 (all population), 2017, CheckMate 274 (PDL1>1%), 2017 2 0% 991 low not evaluable events or deaths (EFS)detailed results CheckMate 274 (all population), 2017 0.70 [0.55; 0.90]
CheckMate 274 (PDL1>1%), 2017 0.55 [0.35; 0.86]
IMvigor-010, 2021 0.89 [0.74; 1.08]
0.74 [0.58 ; 0.95 ] CheckMate 274 (all population), 2017, CheckMate 274 (PDL1>1%), 2017, IMvigor-010, 2021 3 60% 1,800 low not evaluable objective responses (ORR)detailed results JAVELIN Bladder 100 (all population), 2020 7.46 [2.53; 21.97]
JAVELIN Bladder 100 (PDL1>25%), 2020 12.70 [2.11; 76.32]
8.59 [3.41 ; 21.68 ] JAVELIN Bladder 100 (all population), 2020, JAVELIN Bladder 100 (PDL1>25%), 2020 2 0% 1,058 moderate not evaluable AE (any grade)detailed results JAVELIN Bladder 100 (all population), 2020 13.83 [6.28; 30.48]
13.83 [6.28 ; 30.48 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 3.85 [2.72; 5.44]
3.85 [2.72 ; 5.44 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable AE leading to death (grade 5)detailed results JAVELIN Bladder 100 (all population), 2020 4.03 [0.18; 89.68]
4.03 [0.18 ; 89.68 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results JAVELIN Bladder 100 (all population), 2020 93.23 [5.71; 1522.42]
93.23 [5.71 ; 1522.42 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable SAE (any grade)detailed results JAVELIN Bladder 100 (all population), 2020 1.55 [1.09; 2.21]
1.55 [1.09 ; 2.21 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable STRAE (any grade)detailed results JAVELIN Bladder 100 (all population), 2020 68.24 [4.16; 1120.28]
68.24 [4.16 ; 1120.28 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable TRAE (any grade)detailed results CheckMate 274 (all population), 2017 2.84 [2.05; 3.92]
JAVELIN Bladder 100 (all population), 2020 290.72 [105.09; 804.24]
27.97 [0.30 ; 2613.16 ] CheckMate 274 (all population), 2017, JAVELIN Bladder 100 (all population), 2020 2 99% 1,398 low not evaluable TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 1.28 [0.95; 1.74]
JAVELIN Bladder 100 (all population), 2020 133.97 [8.24; 2178.15]
10.57 [0.11 ; 986.65 ] CheckMate 274 (all population), 2017, JAVELIN Bladder 100 (all population), 2020 2 91% 1,388 low not evaluable TRAE leading to death (grade 5)detailed results JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.01 [0.07 ; 60.08 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable TRAE leading to discontinuation (any grade)detailed results JAVELIN Bladder 100 (all population), 2020 73.11 [4.46; 1198.64]
73.11 [4.46 ; 1198.64 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 3.98 [0.18; 88.64]
3.98 [0.18 ; 88.64 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
1.00 [0.06 ; 15.97 ] CheckMate 274 (all population), 2017, JAVELIN Bladder 100 (all population), 2020 2 0% 1,388 low not evaluable Arthralgia TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.01 [0.07 ; 60.08 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Arthritis TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
1.00 [0.02 ; 50.69 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 3.98 [0.18; 88.64]
JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
2.34 [0.21 ; 26.70 ] CheckMate 274 (all population), 2017, JAVELIN Bladder 100 (all population), 2020 2 0% 1,388 low not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 1.99 [0.07; 59.38]
1.99 [0.07 ; 59.38 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Chills TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
1.00 [0.02 ; 50.69 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Colitis TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 1.49 [0.25; 8.98]
JAVELIN Bladder 100 (all population), 2020 4.03 [0.18; 89.68]
1.91 [0.40 ; 9.05 ] CheckMate 274 (all population), 2017, JAVELIN Bladder 100 (all population), 2020 2 0% 1,388 low not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 3.98 [0.18; 88.64]
3.98 [0.18 ; 88.64 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Dermatitis acneiform TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
0.99 [0.02 ; 50.11 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Diabetes TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
1.00 [0.06 ; 15.97 ] CheckMate 274 (all population), 2017, JAVELIN Bladder 100 (all population), 2020 2 0% 1,388 low not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 2.99 [0.31; 28.90]
JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
2.27 [0.32 ; 16.21 ] CheckMate 274 (all population), 2017, JAVELIN Bladder 100 (all population), 2020 2 0% 1,388 low not evaluable Dry skin TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
1.00 [0.02 ; 50.69 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Eczema TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
0.99 [0.02 ; 50.11 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Endocrine disorders TRAE (grade 3-4) detailed results CheckMate 274 (all population), 2017 1.99 [0.07; 59.38]
1.99 [0.07 ; 59.38 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Erythema TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
0.99 [0.02 ; 50.11 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 1.99 [0.07; 59.38]
JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.00 [0.18 ; 22.08 ] CheckMate 274 (all population), 2017, JAVELIN Bladder 100 (all population), 2020 2 0% 1,388 low not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 274 (all population), 2017 2.00 [0.50; 8.06]
2.00 [0.50 ; 8.06 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.01 [0.07 ; 60.08 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
1.00 [0.02 ; 50.69 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.01 [0.07 ; 60.08 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Increase AST TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 1.99 [0.07; 59.38]
1.99 [0.07 ; 59.38 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 3.98 [0.18; 88.64]
3.98 [0.18 ; 88.64 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 20.63 [1.20; 354.60]
20.63 [1.20 ; 354.60 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 6.06 [0.30; 121.47]
6.06 [0.30 ; 121.47 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 3.98 [0.18; 88.64]
3.98 [0.18 ; 88.64 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Myositis TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 4.03 [0.18; 89.68]
4.03 [0.18 ; 89.68 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
1.48 [0.11 ; 19.36 ] CheckMate 274 (all population), 2017, JAVELIN Bladder 100 (all population), 2020 2 0% 1,388 moderate not evaluable Nephritis TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 1.99 [0.07; 59.38]
JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
1.48 [0.11 ; 19.33 ] CheckMate 274 (all population), 2017, JAVELIN Bladder 100 (all population), 2020 2 0% 1,388 low not evaluable Pancreatitis TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.01 [0.07 ; 60.08 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 1.99 [0.07; 59.38]
JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.00 [0.18 ; 22.08 ] CheckMate 274 (all population), 2017, JAVELIN Bladder 100 (all population), 2020 2 0% 1,388 low not evaluable Pruritic rash TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
0.99 [0.02 ; 50.11 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
1.48 [0.11 ; 19.36 ] CheckMate 274 (all population), 2017, JAVELIN Bladder 100 (all population), 2020 2 0% 1,388 moderate not evaluable Pyrexia TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
1.00 [0.02 ; 50.69 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 3.98 [0.18; 88.64]
JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.92 [0.30 ; 28.85 ] CheckMate 274 (all population), 2017, JAVELIN Bladder 100 (all population), 2020 2 0% 1,388 low not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 274 (all population), 2017 8.01 [0.42; 152.12]
8.01 [0.42 ; 152.12 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 274 (all population), 2017 5.99 [0.30; 120.06]
5.99 [0.30 ; 120.06 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
1.00 [0.06 ; 15.97 ] CheckMate 274 (all population), 2017, JAVELIN Bladder 100 (all population), 2020 2 0% 1,388 low not evaluable Urticaria TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
0.99 [0.02 ; 50.11 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Uveitis TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
1.00 [0.02 ; 50.69 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Vitiligo TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
1.00 [0.02 ; 50.69 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.01 [0.07 ; 60.08 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Anaemia AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 1.32 [0.57; 3.04]
1.32 [0.57 ; 3.04 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Arthralgia AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 4.03 [0.18; 89.68]
4.03 [0.18 ; 89.68 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Asthenia AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 0.12 [0.01; 2.36]
0.12 [0.01 ; 2.36 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Back pain AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 0.50 [0.15; 1.66]
0.50 [0.15 ; 1.66 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Constipation AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 4.03 [0.18; 89.68]
4.03 [0.18 ; 89.68 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Cough AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.01 [0.07 ; 60.08 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Decreased appetite AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 0.50 [0.05; 5.54]
0.50 [0.05 ; 5.54 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Diarrhoea AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 2.01 [0.18; 22.29]
2.01 [0.18 ; 22.29 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Fatigue AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 3.04 [0.61; 15.19]
3.04 [0.61 ; 15.19 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.01 [0.07 ; 60.08 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Infusion-related reaction AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 6.06 [0.30; 121.47]
6.06 [0.30 ; 121.47 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Nausea AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 0.50 [0.05; 5.54]
0.50 [0.05 ; 5.54 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Pruritus AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.01 [0.07 ; 60.08 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Pyrexia AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.01 [0.07 ; 60.08 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Rash AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.01 [0.07 ; 60.08 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Skin and subcutaneous tissue disorders AE (grade 3-4)detailed results CheckMate 274 (all population), 2017 12.09 [0.67; 217.24]
12.09 [0.67 ; 217.24 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Vomiting AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 2.02 [0.37; 11.09]
2.02 [0.37 ; 11.09 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable 0.0 200.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 09:12 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 11,288,153,157,290,155,154,289,188,189,239,158,252,253,76,238,236,237
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563